Arca
Skip to content

Heart failure with preserved ejection fraction

Drug research and approvals for heart failure with preserved ejection fraction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 139 studies of heart failure with preserved ejection fraction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 18 drug trials for it since 2013.

  • Recruiting worldwide: 139
  • Trials authorized in Canada: 18
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 139 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 18; search them all in Canada trials
Jun 25, 2025A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of maridebart cafraglutide on mortality and morbidity in…MARIDEBART CAFRAGLUTIDE (AMG 133)AmgenOngoing
Jan 30, 2025Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with…CDR132LNovo NordiskOngoing
Feb 27, 2024A phase 3, double-blind, randomized, placebo-controlled study of levosimendan in pulmonary hypertension patients with heart failure and preserved left…LEVOSIMENDAN (TNX-103)TENAX THERAPEUTICS INCOngoing
Dec 11, 2023Athena: effects of ziltivekimab versus placebo on heart failure symptoms and physical fonction i patients with heart failure with mildly reduced or preserved…ZILTIVEKIMABNovo NordiskOngoing
Nov 8, 2023A phase 2a, double-blind, randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of…DELOCAMTEN (BMS-986435, MYK-224)Bristol-Myers SquibbOngoing
Dec 20, 2022Hermes: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and…ZILTIVEKIMABNovo NordiskOngoing
Sep 9, 2022A phase 2, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ly3540378 in adults with worsening chronic heart…LY3540378 (VOLENRELAXIN)Eli LillyOngoing
Dec 21, 2021A biomarker study assessing the effects of colchicine on inflammation and extra-cellular matrix turnover in patients with heart failure and preserved ejection…COLCHICINEMONTREAL HEART INSTITUTEClosed
Mar 18, 2020A phase 2, multicentre, double-blind, placebo and active control efficacy and safety study to evaluate verinurad combined with allopurinol in heart failure…VERINURAD/ ALLOPURINOLAstraZeneca Pharmaceuticals LPClosed
May 2, 2019A multi-center, double-blind, placebo-controlled phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved…MACITENTANJohnson & JohnsonPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.